Phase II study of the efficacy of peptide T in HIV-positive individuals with cognitive impairment.

Trial Profile

Phase II study of the efficacy of peptide T in HIV-positive individuals with cognitive impairment.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Peptide T (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Aug 2013 Actual initiation date (Jan 2000) added as reported by ClinicalTrials.gov.
    • 21 Aug 2013 Planned patient number is 100 according to ClinicalTrials.gov.
    • 21 Aug 2013 Planned end date (Aug 2013) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top